These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 9988779)

  • 1. Ipriflavone: an important bone-building isoflavone.
    Head KA
    Altern Med Rev; 1999 Feb; 4(1):10-22. PubMed ID: 9988779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Ipriflavone].
    Kitatani K; Morii H
    Nihon Rinsho; 1998 Jun; 56(6):1537-43. PubMed ID: 9648478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Isoflavones and calcified tissues].
    Sukmanskiĭ OI
    Usp Fiziol Nauk; 2002; 33(2):83-94. PubMed ID: 12004580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ipriflavone: pharmacological properties and usefulness in postmenopausal osteoporosis.
    Reginster JY
    Bone Miner; 1993 Dec; 23(3):223-32. PubMed ID: 8148667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Bisphosphonates and bone remodeling: effectiveness in Paget's disease, fibrous dysplasia and osteoporosis].
    Chapurlat R; Meunier PJ
    Rev Chir Orthop Reparatrice Appar Mot; 1998 Nov; 84(8):743-51. PubMed ID: 10192126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ipriflavone: background.
    Gennari C
    Calcif Tissue Int; 1997; 61 Suppl 1():S3-4. PubMed ID: 9263607
    [No Abstract]   [Full Text] [Related]  

  • 7. Soy and its isoflavones: a review of their effects on bone density.
    Brynin R
    Altern Med Rev; 2002 Aug; 7(4):317-27. PubMed ID: 12197783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of osteoporosis and Paget's disease. An appraisal of the risks and benefits of drug treatment.
    Gennari C; Nuti R; Agnusdei D; Camporeale A; Martini G
    Drug Saf; 1994 Sep; 11(3):179-95. PubMed ID: 7811400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ipriflavone modulates IGF-I but is unable to restore bone in rats.
    Deyhim F; Smith BJ; Soung DY; Juma S; Devareddy L; Arjmandi BH
    Phytother Res; 2005 Feb; 19(2):116-20. PubMed ID: 15852487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Paget's disease: the prospects with ipriflavone].
    Bisbocci D; Gallo V; Damiano P; Cantoni R; Suriano A; Chiandussi L
    Recenti Prog Med; 1992 Dec; 83(12):701-6. PubMed ID: 1494710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of ipriflavone treatment on osteoporosis induced by immobilization.
    Földes I; Rapcsák M; Szöör A; Gyarmati J; Szilágyi T
    Acta Morphol Hung; 1988; 36(1-2):79-93. PubMed ID: 3149863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of ipriflavone on bone remodeling in primary hyperparathyroidism.
    Mazzuoli G; Romagnoli E; Carnevale V; Scarda A; Scarnecchia L; Pacitti MT; Rosso R; Minisola S
    Bone Miner; 1992 Oct; 19 Suppl 1():S27-33. PubMed ID: 1422317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soy isoflavones in the management of postmenopausal osteoporosis.
    Atmaca A; Kleerekoper M; Bayraktar M; Kucuk O
    Menopause; 2008; 15(4 Pt 1):748-57. PubMed ID: 18277912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Equol but not genistein improves early metaphyseal fracture healing in osteoporotic rats.
    Kolios L; Sehmisch S; Daub F; Rack T; Tezval M; Stuermer KM; Stuermer EK
    Planta Med; 2009 Apr; 75(5):459-65. PubMed ID: 19241330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased bone resorption with soy isoflavone supplementation in postmenopausal women.
    Harkness LS; Fiedler K; Sehgal AR; Oravec D; Lerner E
    J Womens Health (Larchmt); 2004 Nov; 13(9):1000-7. PubMed ID: 15665657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of ipriflavone in established osteoporosis and long-term safety.
    Agnusdei D; Bufalino L
    Calcif Tissue Int; 1997; 61 Suppl 1():S23-7. PubMed ID: 9263613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soy isoflavone intake increases bone mineral density in the spine of menopausal women: meta-analysis of randomized controlled trials.
    Ma DF; Qin LQ; Wang PY; Katoh R
    Clin Nutr; 2008 Feb; 27(1):57-64. PubMed ID: 18063230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Place of ipriflavone in the therapy of osteoporosis].
    Zsuzsanna B
    Acta Pharm Hung; 1995 Nov; 65(6):229-32. PubMed ID: 8742631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of ipriflavone administration on bone mass and metabolism in ovariectomized women.
    Gambacciani M; Spinetti A; Cappagli B; Taponeco F; Felipetto R; Parrini D; Cappelli N; Fioretti P
    J Endocrinol Invest; 1993 May; 16(5):333-7. PubMed ID: 8320424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Ipriflavone in the treatment of osteoporosis].
    Makita K; Ohta H
    Nihon Rinsho; 2002 Mar; 60 Suppl 3():359-64. PubMed ID: 11979930
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.